Browsing by Author LIM SENG GEE

Select a letter below to browse by last name or type
0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


Showing results 1 to 20 of 146  next >
Issue DateTitleAuthor(s)
20082-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesisZubaidah, R.M. ; Chung, M.C.M. ; Gek, S.T.; Tan, S.B.E.; Lin, Q. ; Seng, G.L. 
20082-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesisZubaidah, R.M. ; Chung, M.C.M. ; Gek, S.T.; Tan, S.B.E. ; Lin, Q. ; Seng, G.L. 
2006A double-blind placebo-controlled study of emtricitabine in chronic hepatitis BLim, S.G. ; Ng, T.M.; Guan, R.; Kung, N.; Krastev, Z.; Volfova, M.; Husa, P.; Lee, S.S.; Chan, S.; Shiffman, M.L.; Washington, M.K.; Rigney, A.; Anderson, J.; Mondou, E.; Snow, A.; Sorbel, J.; Rousseau, F.
2010A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis BTan, A.T.; Koh, S.; Goh, W.; Gehring, A.J.; Bertoletti, A. ; Lim, S.G. ; Zhe, H.Y.
2008A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)Lee, Y.-M. ; Sutedja, D.S.; Dan, Y.-Y. ; Aung, M.-O. ; Zhou, L. ; Lim, S.-G. ; Cheng, C.-L.; Wee, A. ; Wai, C.-T. 
Jun-2008A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)Lee, Y.-M. ; Sutedja, D.S.; Wai, C.-T. ; Dan, Y.-Y. ; Aung, M.-O. ; Zhou, L. ; Cheng, C.-L.; Wee, A.; Lim, S.-G. 
2006A randomized, placebo-controlled trial of thymosin-α1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis BLim, S.G. ; Wai, C.-T. ; Lee, Y.M. ; Dan, Y.Y.; Sutedja, D.S.; Wee, A. ; Suresh, S.; Wu, Y.J.; Machin, D.; Lim, C.C.; Fock, K.M.; Koay, E.; Bowden, S.; Locarnini, S.; Ishaque, S.M.
2006A randomized, placebo-controlled trial of thymosin-α1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis BLim, S.G. ; Wai, C.-T. ; Lee, Y.M. ; Dan, Y.Y.; Sutedja, D.S.; Wee, A. ; Suresh, S.; Wu, Y.J.; Machin, D.; Lim, C.C.; Fock, K.M.; Koay, E. ; Bowden, S.; Locarnini, S.; Ishaque, S.M.
2004Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplantWai, C.-T.; Prabhakaran, K. ; Wee, A. ; Lee, Y.-M.; Dan, Y.-Y.; Sutedja, D.S.; Mak, K.; Isaac, J. ; Lee, K.-H. ; Lee, H.-L.; Da, Costa M. ; Lim, S.-G. 
2003Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis BHadziyannis, S.J.; Tassopoulos, N.C.; Heathcote, E.J.; Chang, T.-T.; Kitis, G.; Rizzetto, M.; Marcellin, P.; Lim, S.G. ; Goodman, Z.; Wulfsohn, M.S.; Xiong, S.; Fry, J.; Brosgart, C.L.
2003Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BMarcellin, P.; Chang, T.-T.; Lim, S.G. ; Tong, M.J.; Sievert, W.; Shiffman, M.L.; Jeffers, L.; Goodman, Z.; Wulfsohn, M.S.; Xiong, S.; Fry, J.; Brosgart, C.L.
Aug-2007Age in Guiding Strategy in Hepatitis A VaccinationWai, C.-T. ; Mak, B.; Aung, M.O. ; Lim, S.-G. 
2003An anti-HIV-1 gp120 antibody expressed as an endocytotic transmembrane protein mediates internalization of HIV-1Tan, Y.-J.; Lim, S.-P.; Ting, A.E.; Goh, P.-Y.; Tan, Y.H.; Lim, S.G. ; Hong, W.
Apr-2012APASL consensus statements and management algorithms for hepatitis C virus infectionOmata, M.; Kanda, T.; Yu, M.-L.; Yokosuka, O.; Lim, S.-G. ; Jafri, W.; Tateishi, R.; Hamid, S.S.; Chuang, W.-L.; Chutaputti, A.; Wei, L.; Sollano, J.; Sarin, S.K.; Kao, J.-H.; McCaughan, G.W.
2007Applicability of cost-effectiveness analysis to management of chronic hepatitis BDan, Y.Y.; Lim, S.G. 
2006Are in vitro hepatitis B core promoter mutations important for clinical alterations in viral load?Cheng, Y. ; Seet, B.L.; Ong, C.S.L.; Wasser, S. ; Lim, S.G. ; Tan, T.M.C. ; Peter, F.J. 
2010Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaOmata, M.; Tateishi, R.; Yoshida, H.; Shiina, S.; Lesmana, L.A.; Budihusodo, U.; Lesmana, C.R.; Chen, P.-J.; Lin, S.-M.; Liaw, Y.F.; Kudo, M.; Lee, J.M.; Choi, B.I.; Poon, R.T.P.; Cheng, A.L.; Jia, J.-D.; Obi, S.; Han, K.H.; Jafri, W.; Chow, P.; Lim, S.G. ; Chawla, Y.K.; Gani, R.A.; Putranto, T.A.; Sarin, S.K.
Jul-2009Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis BZeuzem, S.; Gane, E.; Liaw, Y.-F.; Lim, S.G. ; DiBisceglie, A.; Buti, M.; Chutaputti, A.; Rasenack, J.; Hou, J.; O'Brien, C.; Nguyen, T.T.; Jia, J.; Poynard, T.; Belanger, B.; Bao, W.; Naoumov, N.V.
2005Bilirubin appears to be the only independent variable affecting mortality on liver transplant waiting list if waiting time exceeds 1 yearLee, Y.-M. ; Wai, C.-T. ; Da, Costa M. ; Lee, K.-H.; Sutedja, D.; Tan, K.-C.; Isaac, J. ; Lim, S.-G. 
2005Bilirubin appears to be the only independent variable affecting mortality on liver transplant waiting list if waiting time exceeds 1 yearLee, Y.-M. ; Wai, C.-T. ; Da, Costa M. ; Lee, K.-H. ; Sutedja, D.; Tan, K.-C.; Isaac, J. ; Lim, S.-G.